Skip to content
AnalystLens

BridgeBio Pharma Quarterly Report for Q1 Ended Mar 31, 2024

Filing Date
Filed May 2, 2024
Period End
March 31, 2024
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Oct ’21Oct ’21
  3. Material agreement8-K · Sep ’23Sep ’23
  4. Material agreement8-K · Aug ’26Aug ’26

Summary

Summary of the 10-Q filed May 2, 2024. Cited figures are marked; the original filing is the authoritative source.

BridgeBio Pharma, Inc. (BridgeBio) reported a net loss of $36.2 milliona for the three months ended March 31, 2024, a substantial improvement from a net loss of $142.7 million in the prior-year period.

Revenue rose to $211.1 millionb from $1.8 million, driven mainly by $201.2 million of upfront license fee and services revenue from the Bayer Agreement and the KKC Agreement, plus $9.9 million from the terminated Navire-BMS License Agreement. Research and development expenses increased to $141.0 million from $92.9 million, and selling, general and administrative expenses increased to $65.8 million from $31.1 million, including $14.0 million of nonrecurring deal-related expenses. The balance sheet strengthened over the quarter.

Cash, cash equivalents and marketable securities were $519.7 millionc at March 31, 2024, compared with $375.9 million at December 31, 2023, supported by a $450.0 million Initial Term Loan under a Financing Agreement with Blue Owl Capital Corporation and about $315.3 million of net proceeds from public offerings. The company used the proceeds to fully repay its prior term loan, which carried a $26.6 million loss on extinguishment of debt. Total stockholders' deficit narrowed to $(1,037.4) million from $(1,343.0) million, and the accumulated deficit was $2.6 billion.

The company stated it expects its existing resources to fund operations for at least the next 12 months. Key forward-looking items include a $500.0 milliond funding agreement payable upon first FDA approval of acoramidis, in exchange for a 5% royalty on global net sales of acoramidis, and a requirement to deposit 75% of proceeds from certain asset sales into an escrow account under the Financing Agreement.

The company also recorded new restructuring plans with an estimated remaining $12.0 million to $16.0 million in charges. A subsequent event on April 30, 2024 was a $200.0 million private financing of BridgeBio Oncology Therapeutics, which the company is still evaluating.

Key Highlights

  1. Net loss narrowed to $36.2 million for Q1 2024 from $142.7 million in Q1 2023.
  2. Revenue of $211.1 million, up from $1.8 million, mainly from the upfront license fees under the Bayer Agreement ($135.0 million upfront) and the KKC Agreement ($100.0 million upfront).
  3. Cash, cash equivalents and marketable securities of $519.7 million at March 31, 2024, up from $375.9 million at December 31, 2023.
  4. Refinanced debt: fully repaid the Amended Loan Agreement for $475.8 million using a $450.0 million Initial Term Loan under the Financing Agreement, recognizing a $26.6 million loss on extinguishment of debt.
  5. Raised approximately $315.3 million in net proceeds from common stock public offerings, including a March 2024 follow-on offering of 9,913,793 shares at $29.00 per share.
  6. Research and development expenses rose to $141.0 million from $92.9 million, and SG&A rose to $65.8 million from $31.1 million.
  7. Stockholders' deficit narrowed to $(1,037.4) million at March 31, 2024 from $(1,343.0) million at December 31, 2023.

Follow one dollar

For each $1.00 of revenue in Q1 FY2024, BridgeBio Pharma lost $0.17.

  1. Revenue$211.1M100.0%
  2. Cost of revenue−$598,0000.3%
  3. Gross profit$210.5M99.7%
  4. Operating costs−$210.2M99.6%
  5. Operating income$343,0000.2%
  6. Interest, other & tax−$35.6M16.8%
  7. Net income−$35.2M16.7%
Computed from 10-QQ1 FY2024filed May 2, 2024Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

Q1 FY2024 against Q1 FY2023

Line itemQ1 FY2024Q1 FY2023Change
Revenue$211.12M$1.83M+11461.9%
Cost of Revenue$598K$651K−8.1%
Gross Profit$210.52M$1.18M+17816.8%
R&D Expenses$140.97M$92.86M+51.8%
SG&A Expenses$65.81M$31.11M+111.5%
Operating Expenses$210.78M$127.99M+64.7%
Operating Income$343K-$126.16M+100.3%
Interest Expense$8.57M$8.55M+0.3%
Net Income-$35.22M-$140.16M+74.9%
EPS (Basic)$-0.20$-0.92+78.3%
EPS (Diluted)$-0.20$-0.92+78.3%
Shares Outstanding (Basic)178.71M152.65M+17.1%
Shares Outstanding (Diluted)178.71M152.65M+17.1%

Frequently Asked Questions

  1. Why did BridgeBio report a net loss that is much smaller than in the prior year?

    Revenue increased to $211.1 million from $1.8 million, mainly from license revenue of $201.2 million recognized from the upfront fees under the Bayer and KKC agreements. Income from operations was $0.3 million, compared with a loss from operations of $126.2 million in the prior-year quarter. Net loss was still affected by $26.6 million of loss on extinguishment of debt and $23.5 million of interest expense.

  2. What is the Financing Agreement and what does it require?

    On January 17, 2024, the company entered into a Financing Agreement with Blue Owl Capital Corporation as administrative agent, providing up to $750.0 million, including a $450.0 million Initial Term Loan funded on January 17, 2024. The loan bears interest at a base rate plus 5.75% or Term SOFR plus 6.75%. The company must keep a minimum unrestricted cash balance of $70.0 million and deposit 75% of net proceeds from certain asset sales, including the Bayer and Kyowa Kirin licenses, into an escrow account.

  3. What is the funding agreement tied to acoramidis?

    The company entered into a Funding Agreement on January 17, 2024, under which the purchasers agreed to pay $500.0 million (net of certain transaction expenses) upon the first FDA approval of acoramidis. In return, the purchasers receive 5% of global net sales of acoramidis, which may adjust to a maximum of 10% in 2027. As of March 31, 2024, no proceeds had been received under this agreement.

  4. How much cash does BridgeBio have and how long will it last?

    As of March 31, 2024, the company had cash, cash equivalents and marketable securities of $519.7 million and restricted cash of $0.1 million. The company expects its cash, cash equivalents, marketable securities, restricted cash and receivables from licensing and collaboration agreements to fund operations for at least the next 12 months from the filing date, based on current operating plans. It also expects to keep incurring operating and net losses over the next several years.

  5. What happened with the Navire-BMS License Agreement?

    In March 2024, BMS notified the company that it was terminating the Navire-BMS License Agreement effective June 2024. As a result, the remaining research and development services revenue of $9.9 million was recognized in the first quarter of 2024, and future royalty payments under the agreement are no longer achievable. The company also recorded additional restructuring plans with an estimated remaining $12.0 million to $16.0 million in charges.